INmune Bio (NASDAQ:INMB) Announces Quarterly Earnings Results

INmune Bio (NASDAQ:INMB - Get Free Report) released its financial results for the quarter on Thursday. The company reported earnings per share (EPS) of ($0.40), which exceeded analysts' expectations of ($0.54) by $0.14, according to Zacks.

INmune Bio's Stock Performance

During mid-day trading on Friday, INmune Bio's shares fell by $0.27, bringing the stock price down to $7.14. Approximately 61,057 shares were traded, in contrast to the average trading volume of 241,182 shares. The company's market capitalization stands at $189.86 million, with a price-to-earnings (PE) ratio of -3.25 and a beta value of 1.93. Over the past 50 days, the stock's simple moving average has been $8.39, while the 200-day simple moving average is $6.37. Over the last year, INmune Bio's shares have reached a low of $4.32 and a high of $12.72.

Analyst Ratings

Multiple research firms have provided insights on INmune Bio. On February 13th, Maxim Group raised its target price for the company from $22.00 to $30.00 and assigned it a "buy" rating. Scotiabank also increased their target price from $22.00 to $23.00, giving a "sector outperform" rating in a report dated February 11th. RODMAN & RENSHAW upgraded INmune Bio to a "strong-buy" rating on January 28th. Moreover, Rodman & Renshaw began coverage on the company, establishing a "buy" rating with a target price of $23.00. Currently, five investment analysts have rated the stock as a buy, while one has assigned a strong buy rating. According to MarketBeat.com, the overall average rating for INmune Bio is "Buy," with a consensus target price of $22.80.

About INmune Bio

INmune Bio, Inc. is a clinical-stage immunology company that focuses on developing innovative therapies designed to reprogram the innate immune system of patients in order to treat various diseases in the United States. The firm aims to develop and commercialize product candidates targeting hematologic malignancies, solid tumors, and chronic inflammation.

Earnings, Stocks, Performance